Vistagen appoints Angel S. Angelov, MD, MBA, as Chief Medical Officer effective May 18, 2026

Vistagen Therapeutics, Inc.

Dr. Angelov brings two decades of industry experience including roles at Karuna Therapeutics, Neurocrine Biosciences, Novartis, and Teva.
Annual base salary of $425,000, $50,000 signing bonus paid in two tranches, and eligibility for annual discretionary bonus (target 45% of salary).
Inducement grant of 150,000 stock options at $0.5955 per share, vesting over 4 years with 25% cliff at one year.
Dr. Angelov is board-certified in psychiatry and holds an MBA from Wharton; will lead clinical development for Vistagen's pherine pipeline.

item 5.02item 7.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Angel S. Angelov, M.D., MBA

Chief Medical Officer

VTGN · Vistagen Therapeutics, Inc.

Effective: 2026-05-18
Filed: May 19, 2026 20:30 UTC

On May 18, 2026 (the “ Effective Date ”), Vistagen Therapeutics, Inc. (the “ Company ”) appointed Angel S. Angelov, M.D., MBA to serve as the Company’s Chief Medical Officer.

Source: SEC EDGAR

accession 0001628280-26-036492

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.